David Jones, SVP & Chief Commercial Officer of EyePoint Pharmaceuticals Inc (EYPT, Financial), executed a sale of 35,066 shares in the company on January 23, 2024, according to a recent SEC filing.
EyePoint Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development and commercialization of treatments for ocular diseases. The company's portfolio includes therapies for conditions such as uveitis, diabetic macular edema, and other eye-related diseases.
Over the past year, the insider has sold a total of 35,066 shares and has not made any purchases of the company's stock.
The insider transaction history at EyePoint Pharmaceuticals Inc reveals a pattern of insider activity. In the past year, there have been 3 insider buys and 17 insider sells.
On the date of the insider's most recent transaction, shares of EyePoint Pharmaceuticals Inc were trading at $22.68 each, giving the company a market capitalization of $1.169 billion.
The stock's price-to-GF-Value ratio stands at 3.86, with a GF Value of $5.88, indicating that EyePoint Pharmaceuticals Inc is significantly overvalued according to the intrinsic value estimate by GuruFocus.
The GF Value is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
